glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical Comparative renal outcomes of matched

Description

November 2023: A report filed in the Journal of the American Medical Association found a link between taking Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) and an increased risk of adverse gastrointestinal events such as gastroparesis

Prevention of cardiorenal complications and beyond With the improvement in the management of cardiovascular risk factors, a progressive decline in the annual incidence rate of cardiovascular morbidity and mortality has been observed in both the general population and the diabetic population over the past decades

doi: 10.1136/gut.24.2.114

The comparator group, defined as patients who did not initiate GLP-1RA therapy during the study period, was constructed by aligning nonusers to GLP-1RA users within a 1-week window of the initiation date to ensure temporal comparability of treatment assignment